Michelle Jones, MD
Infectious Disease · Atlanta, GANPI 1316127020
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,909 of the $31,855 with a category attached, or 62.5%. Gilead accounts for 79.7% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $14,619, more than ten times the $646 reported in 2019. Among infectious disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $97.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$25K
- Viiv Healthcare Company$2K
- Merck$600
- AbbVie$483
- Astellas Pharma US Inc$373
- Johnson & Johnson$367
- plus $2K from 25 others
Across 2 payments — averaging $5165.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$10K
What the payments were for
- Speaking & faculty fees$19,90963%
- Travel & lodging$4,76015%
- Food & beverage$7,15922%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 80 | $25,397 |
| Viiv Healthcare Company | 42 | $2,157 |
| Merck | 28 | $600 |
| AbbVie(2 entities) | 25 | $483 |
| Astellas Pharma US Inc | 15 | $373 |
| Johnson & Johnson | 22 | $367 |
| Paratek Pharmaceuticals, Inc. | 17 | $330 |
| Theratechnologies Inc. | 16 | $308 |
| Melinta Therapeutics, LLC | 8 | $217 |
| Insmed, Inc. | 8 | $214 |
| La Jolla Pharmaceutical Company | 9 | $196 |
| Napo Pharmaceuticals Inc | 10 | $188 |
| Cumberland Pharmaceuticals, Inc. | 8 | $162 |
| Shionogi Inc | 4 | $102 |
| Pfizer | 3 | $86 |
| Dynavax Technologies Corporation | 4 | $80 |
| Aimmune Therapeutics, Inc. | 3 | $77 |
| EMD Serono, Inc. | 3 | $64 |
| Ferring Pharmaceuticals Inc. | 3 | $61 |
| Janssen Scientific Affairs, LLC | 3 | $50 |
| Angiodynamics, Inc. | 1 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Octapharma USA, Inc. | 1 | $42 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $38 |
| Mayne Pharma Commercial LLC | 2 | $38 |
| Hologic Sales And Service, LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| AstraZeneca | 1 | $22 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| Sanofi | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$11,538
How this compares
$31,855 in reported general payments places this provider in the 90th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 119 | $588,711 |
| TivicayDolutegravir Sodium | 28 | $84,906 |
| PifeltroDoravirine | 25 | $60,526 |
| PrezcobixDarunavir/Cobicistat | 19 | $48,276 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $31,639 |
| IsentressRaltegravir Potassium | 12 | $24,090 |
| Daptomycin | 30 | $19,198 |
| CeftriaxoneCeftriaxone Sodium | 40 | $6,062 |
| ErtapenemErtapenem Sodium | 11 | $4,688 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 12 | $4,042 |
| Ampicillin Sodium | 13 | $3,417 |
| Cefazolin Sodium | 21 | $881 |
| Ethambutol Hcl | 13 | $724 |
| Azithromycin | 15 | $679 |
| Rifampin | 14 | $661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $25,397 | $620,350133 claims |
| Viiv Healthcare CompanyTivicay | $2,157 | $84,90628 claims |
| MerckPifeltro, Isentress | $600 | $84,61637 claims |
| Johnson & JohnsonPrezcobix | $367 | $48,27619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Atlanta
- Zandraetta Tims-CookAtlanta$848K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Colleen KraftAtlanta$103K
- Walter OrensteinAtlanta$78K
- Nadine RouphaelAtlanta$66K
- Kimberly WorkowskiAtlanta$53K
- Bernard BransonAtlanta$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.